Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas

Leukemia volume 19, pages 143–145 (2005)Cite this article

TO THE EDITOR

High-dose chemotherapy followed by stem cell rescue has improved the response rate and the overall survival of multiple myeloma patients. However, the disease remains incurable and the majority of the patients develop progressive disease within several years. Treatment options for patients with relapsed or refractory disease are limited.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

    Article  CAS  Google Scholar 

  2. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW . An UK myeloma forum phase II study of thalidomide: long term follow-up and recommendations for treatment. Leukemia Res 2003; 27: 909–914.

    Article  CAS  Google Scholar 

  3. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34–39.

    Article  Google Scholar 

  4. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422–424.

    Article  CAS  Google Scholar 

  5. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832–836.

    CAS  PubMed  Google Scholar 

  6. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM . Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 28: 1145–1150.

    Article  CAS  Google Scholar 

  7. Ribas C, Colleoni G, Almeida M, Duch CR, Ohashi C, Segreto R et al. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. Acta Oncol 2004; 43: 215–216.

    Article  Google Scholar 

  8. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614–1615.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Erasmus MC, Department of Hematology, Rotterdam, The Netherlands

    K L Wu & P Sonneveld

  2. Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands

    H H Helgason & W M Smit

  3. Erasmus MC, HOVON Data Center, Rotterdam, The Netherlands

    B van der Holt

  4. Department of Hematology, Leyenburg Hospital, Rotterdam, The Netherlands

    P W Wijermans

  5. Department of Hematology, University Medical Center, Utrecht, The Netherlands

    H M Lokhorst

Authors
  1. K L Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H H Helgason
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B van der Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P W Wijermans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H M Lokhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W M Smit
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Sonneveld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, K., Helgason, H., van der Holt, B. et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 19, 143–145 (2005). https://doi.org/10.1038/sj.leu.2403568

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403568

This article is cited by

Search

Advanced search

Quick links